Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The "Beyond TME Origins" clinical trial is studying patients who have experienced a recurrence of colorectal cancer in the pelvic area. The goal of the trial is to understand the risk factors that might lead to this recurrence by looking at patients' original staging scans and surgical samples. Additionally, the trial will use a special type of imaging called MRI to better assess the recurrence. Participants will be followed for three years to monitor their treatment and outcomes.
To be eligible for this trial, participants must be at least 16 years old and have previously been diagnosed with colorectal adenocarcinoma, which is a type of cancer that starts in the lining of the colon or rectum. They should also have had surgery for their initial cancer and be able to undergo an MRI scan. Importantly, patients with certain types of advanced cancer that cannot be treated or those without the necessary medical records may not qualify. If you decide to participate, you will be contributing to valuable research that could help improve future treatments for colorectal cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Had a primary colorectal adenocarcinoma proven by biopsy taken as part of routine clinical practice
- • 2. Has a confirmed diagnosis of recurrent pelvic colorectal cancer
- • 3. Has previously completed surgical treatment of primary adenocarcinoma of the colon, sigmoid colon or rectum
- • 4. Are able to undergo high resolution MRI for staging prior to treatment decisions
- • 5. Have provided written informed consent to participate in the study
- • 6. Be aged 16 years or over
- Exclusion Criteria:
- • 1. Have irresectable extra-pelvic metastatic disease
- • 2. Original baseline staging and preoperative restaging scans (MR for rectal and sigmoid cancers and/or CT for colon and sigmoid cancers) are unavailable
- • 3. Original preoperative, surgical and adjuvant treatment has not been documented or is unavailable
About Imperial College London
Imperial College London is a world-renowned research institution based in the United Kingdom, recognized for its commitment to advancing medical science and improving patient care through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, Imperial combines expertise across various fields, including medicine, engineering, and business, to drive breakthroughs in healthcare. The institution’s robust clinical trial programs are designed to evaluate new therapies and interventions, ensuring rigorous scientific standards and ethical practices while aiming to translate research findings into tangible benefits for patients and society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oslo, , Norway
Harrow, London, United Kingdom
Oxford, Oxfordshire, United Kingdom
Sutton, , United Kingdom
Patients applied
Trial Officials
Gina Dr Brown, MD
Principal Investigator
Imperial College London
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials